Format

Send to

Choose Destination
Breast. 2013 Oct;22(5):845-9. doi: 10.1016/j.breast.2013.02.020. Epub 2013 Mar 22.

Treatment of peritoneal carcinomatosis from breast cancer by maximal cytoreduction and HIPEC: a preliminary report on 5 cases.

Author information

1
Dipartimento di Chirurgia "P. Valdoni", Università di Roma "Sapienza", Azienda Policlinico Umberto I°, Viale del Policlinico 161, 00155 Rome, Italy. Electronic address: maurizio.cardi@uniroma1.it.

Abstract

Although peritoneal carcinomatosis from breast cancer is a rare event it frequently causes morbidity and mortality. Current literature provides scarce information on its management. We report outcomes in 5 patients (mean age 59.4 years) with peritoneal carcinomatosis from breast cancer treated with maximal cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) by the closed technique, at 40 °C for 1 h with cisplatin 75 mg/m(2). The primary breast cancer was a ductal carcinoma in 3 patients and a lobular carcinoma in 2. Mean peritoneal cancer index was 20.2. In 4 of the 5 patients surgery achieved macroscopic complete cytoreduction. One patient died of disease at 56 months, 4 are alive and disease-free at 13, 45, 74 and 128 months. These encouraging outcomes suggest that cytoreduction and HIPEC is a promising approach to offer to highly selected patients with peritoneal carcinomatosis from breast cancer and that this approach merit investigation in a larger series.

KEYWORDS:

Breast cancer; Cytoreduction; HIPEC; Peritoneal metastases

PMID:
23523180
DOI:
10.1016/j.breast.2013.02.020
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center